MedTrace Logo

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

NCT07527923 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2026-06-25

No results posted yet for this study

Summary

This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans.

The study is looking at:

* What side effects REGN20423 might cause
* How much REGN20423 is in the blood at different times
* How well REGN20423 works in adults with atopic dermatitis
* Whether the body makes antibodies against REGN20423
* How the body changes after having REGN20423, which can help researchers understand why REGN20423 works better in some people than others
* What the best dose of REGN20423 is

Conditions

Interventions

OTHER

Placebo

Administered per the protocol

DRUG

REGN20423

Administered per the protocol

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-22
Primary Completion
2028-06-23
Completion
2028-06-23
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07527923 on ClinicalTrials.gov